Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $67.89 in the latest trading session, marking a -1.38% move from the prior day.

Zacks Equity Research

Novavax Expands Coronavirus Vaccine Manufacturing Deal in India

by Zacks Equity Research

Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.

Zacks Equity Research

BioNTech Gets New Funding for Coronavirus Vaccine Development

by Zacks Equity Research

BioNTech (BNTX) receives grant of up to almost $445 million to support development and potential approval of its coronavirus vaccine candidate.

Zacks Equity Research

Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.

Zacks Equity Research

Pfizer Seeks to Raise Coronavirus Study Enrollment Target

by Zacks Equity Research

Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.

Zacks Equity Research

Implied Volatility Surging for Moderna (MRNA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Zacks Equity Research

AstraZeneca Resumes UK Study on Coronavirus Vaccine Candidate

by Zacks Equity Research

AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in U.K. resume after the Medicines Health Regulatory Authority confirms that it is safe to do so.

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $57.56 in the latest trading session, marking a +1.16% move from the prior day.

Zacks Equity Research

Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU

by Zacks Equity Research

Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.

Zacks Equity Research

Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies

by Zacks Equity Research

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.